NCT03660202Unknown不适用
A Prospective Multicenter Single-arm Clinical Trial Assessing the Safety and Effectiveness of Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold for the Treatment of Coronary Artery Disease: FUTURE III
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- The number and rate of Target Lesion Failure(TLF)
研究概览
简要总结
The FUTURE-III study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale First-in-Man clinical trial.
详细描述
This study is a prospective, multicenter, single-arm trial in patients with coronary artery disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels. The goal is to evaluate the safety and effectiveness of Firesorb to support the approval of the Chinese Food and Drug Administration (CFDA) for this product.All subjects will undergo clinical follow-up at 1-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year post-index procedure. A total of 1200 subjects will be recruited, including 96 with long lesion (the scaffold to be used with a length of 33mm or 38mm) and 215 in the experimantal group of FUTURE-II clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75 years of age, males or non-pregnant females;
- •With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction;
- •Patients with indications for coronary artery bypass graft surgery; To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up.
- •Angiographic Inclusion Criteria:
- •General Specification Subgroup:
- •One or two de novo target lesions:
- •If two target lesions are present, they must be present in different epicardial vessels and both must satisfy the angiographic eligibility criteria.
- •Note: The definition of epicardial vessels means the LAD, LCX and RCA and their branches. Thus, the patient must not have lesions requiring treatment in e.g. both the LAD and a diagonal branch.
- •b. Target lesion(s) must be located in a native coronary artery with a visually estimated stenosis ≥ 70% or ≥ 50% and < 100% with clinical evidence of myocardial ischemia, a thrombolysis in myocardial infarction (TIMI) flow of ≥
- •Target lesion vessel length ≤25mm by visual estimation, target vessel diameter 2.5mm-4.0mm.
- •c. Each target lesion may be covered with one stent.
- •Long Lesion Subgroup:
- •One de novo target lesion.
- •Target lesion(s) must be located in a native coronary artery with a visually estimated stenosis ≥ 70% or ≥ 50% and < 100% with clinical evidence of myocardial ischemia, a thrombolysis in myocardial infarction (TIMI) flow of ≥
- •Target lesion vessel length ≤34mm by visual estimation, target vessel diameter 3.0mm-4.0mm.
- •Each target lesion may be covered with one stent.
排除标准
- •Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal;
- •Implantation of stent in target vessel within 1 year;
- •Patients with planned intervention again within six months;
- •Severe congestive heart failure (NYHA III and above) ,or left ventricular ejection fraction <40% (ultrasound or left ventricular angiography);
- •Preoperative renal function serum creatinine >2.0mg/DL; receiving hemodialysis;
- •Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy;
- •Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies;
- •The patient's life expectancy is less than 12 months;
- •Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame;
- •Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements;
- •Heart transplantation patients;
- •The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia;
- •Cancer need chemotherapy;
- •Immunosuppression and autoimmune diseases, planned or undergoing immunosuppressive therapy;
- •Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc;
- •Within six months for elective surgery requires stopping aspirin, Clopidogrel patients;
- •Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; known or suspected liver disease (such as hepatitis);
- •Peripheral vascular disease, 6F catheter is not available.
- •Angiographic Exclusion Criteria:
- •Left main coronary artery disease;
- •Severe triple vessel lesion and required revascularization.
- •The following exclusion criteria apply to the target lesion(s) or target vessel(s):
- •Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).
- •Lesion located within 3 mm of the origin of the Left Anterior Descending Artery (LAD) or left circumflex artery (LCX).
- •Lesion involving a bifurcation with a:
- •(1)side branch ≥ 2.5 mm in diameter, or (2)side branch with diameter stenosis ≥ 50%, or (3)side branch requiring guide wire, or (4)side branch requiring dilatation.
- •Anatomy proximal to or within the lesion that may impair delivery of Firesorb :
- •Extreme angulation (≥ 90°) proximal to or within the target lesion.
- •Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.
- •Moderate or heavy calcification proximal to or within the target lesion.
- •Lesion or vessel involves a myocardial bridge.
- •Vessel contains thrombus as indicated in the angiographic images or by IVUS or OCT.
- •Vessel has been previously treated with a stent at any time prior to the index procedure such that the Firesorb or XIENCE would need to cross the stent to reach the target lesion.
- •Vessel has been previously treated and the target lesion is within 5 mm proximal or distal to a previously treated lesion.
- •Lesion which prevents successful balloon pre-dilatation, defined as full balloon expansion with the following outcomes:
- •Residual %DS is a maximum of < 40% (per visual estimation), ≤ 20% is strongly recommended.
- •TIMI Grade-3 flow (per visual estimation).
- •No angiographic complications (e.g. distal embolization, side branch closure).
- •No dissections National Heart Lung and Blood Institute (NHLBI) grade D-F.
- •No chest pain lasting > 5 minutes.
- •No ST depression or elevation lasting > 5 minutes.
研究组 & 干预措施
Single Arm
Experimental
Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
干预措施: Firesorb (Device)
结局指标
主要结局
The number and rate of Target Lesion Failure(TLF)
时间窗: 1 year after index procedure
Target Lesion Failure is defined as the composited endpoints of cardiac death,target vessel myocardial infarction and ischemia-driven target lesion revascularization.
次要结局
- Acute Success-Procedural Success(At time of procedure up to 7 days in hospital)
- The number and rate of Acute Success-Device Success(From the start of index procedure to end of index procedure)
- Device-oriented composite endpoints (Target Lesion Failure)(1 month,6 months,2 years,3 years,4 years and 5 years after index procedure)
- Patient-oriented clinical composite endpoint (PoCE)(1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure)
- The number and rate of Target Vessel Revascularization (TVR)(1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure)
- Death (Cardiac, Vascular, Non-cardiovascular)(1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure)
- The number and rate of Myocardial Infarction (MI)(1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure)
- The number and rate of Target Lesion Revascularization (TLR)(1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure)
- The number and rate of Any Revascularization(1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure)
- The number and rate of Scaffold Thrombosis (per ARC definition)(1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-IICoronary Artery DiseaseNCT02890160Shanghai MicroPort Medical (Group) Co., Ltd.430
进行中（未招募）
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery DiseaseCoronary Artery DiseaseNCT05205499Biotyx Medical (Shenzhen) Co., Ltd.1,059
已完成
3 期
NOVOCART® Inject Plus for Cartilage Defects of the KneeCartilage Defects of the KneeNCT03319797Tetec AG100
Unknown
不适用
NeoVas Bioresorbable Coronary Scaffold Registry StudyCoronary Artery DiseaseNCT02305472Lepu Medical Technology (Beijing) Co., Ltd.825
已完成
不适用
The ILLUMINA Study. (ILLUMINA)Peripheral Arterial DiseaseNCT03510676CID - Carbostent & Implantable Devices100